By inhibiting PLK1, these combinations can address the issue of drug resistance to certain chemotherapy agents and act as radiation sensitizers, thereby enhancing the effectiveness of tumor chemoradiotherapy (5–7). This evidence concerns the gene PLK1 and neoplasm.